Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 34: 1668-1675, 1988;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morrison, S. L.
Right arrow Articles by Wims, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morrison, S. L.
Right arrow Articles by Wims, L. A.

Clinical Chemistry, Vol 34, 1668-1675, Copyright © 1988 by American Association for Clinical Chemistry

Production and characterization of genetically engineered antibody molecules

SL Morrison, S Canfield, S Porter, LK Tan, MH Tao and LA Wims
Department of Microbiology, Columbia University College of Physicians and Surgeons, New York, NY 10032.

Expression of antibody heavy- and light-chain genes by transfection permits the production of monoclonal antibodies with improved biological and antigen-binding properties. The immunoglobulin genes are placed in vectors containing a gene for encoding a protein that provides a biochemically selectable function in eukaryotic cells; these vectors are transfected into myeloma and hybridoma cells. Selection of drug-resistant cells permits the efficient isolation of the rare cells that express the transfected DNA. By placing heavy and light chains on plasmids with different selectable markers, one can deliver heavy- and light-chain genes simultaneously to the same cell. The transfected immunoglobulin genes are efficiently expressed and the proteins produced are a faithful mirror of the genes that were introduced. Using the standard techniques of genetic engineering and gene transfection, we can now produce antibodies of widely varying structures, including chimeric antibodies with segments derived from different species. These antibodies provide useful reagents to study structure-function relationships within the antibody molecule. Ultimately it will be possible to produce a new generation of antibody molecules with improved antigen-binding properties and effector functions.


The following articles in journals at HighWire Press have cited this article:


Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Sano, S. Vajda, C. L. Smith, and C. R. Cantor
Engineering subunit association of multisubunit proteins: A dimeric streptavidin
PNAS, June 10, 1997; 94(12): 6153 - 6158.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
T Sano, C. Smith, and C. Cantor
Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates
Science, October 2, 1992; 258(5079): 120 - 122.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American Association for Clinical Chemistry.